ArticleFrontiers in pharmacology2025
Intrathecal silymarin administration improves recovery after compression spinal cord injury: evidence for neuroprotection, antioxidant, and anti-inflammatory action.
Article in Frontiers in pharmacology, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 2 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
2 citing papers in PubMed.
- Anxiolytic and antidepressant effects of astaxanthin: behavioral and mechanistic insights in a rat model.Frontiers in pharmacology · 2026Article
- Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
6 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Background: Spinal cord injury (SCI) is a debilitating disorder that affects people's quality of life. Unfortunately, there is no definitive drug for treating SCI. Additionally, the adverse effects of existing non-approved drugs make it necessary to research and investigate the effects of new multi-target agents to combat SCI complications. Purpose: This study specifically investigates the effect of a multi-target phytochemical silymarin (SIL), known for its potent neuroprotective, anti-inflammatory, and antioxidant properties, on sensorimotor function after SCI. Materials and Methods: In total, 30 male Wistar rats were divided into five distinct groups: Sham, SCI, and three additional groups that received SIL at dosage levels of 0.1, 0.2, and 0.4 μmol. Following the injury, behavioral tests such as acetone drop, hot plate, von Frey, BBB, and inclined plane were conducted along with weight measurements for 4 weeks. Serum samples were analyzed to assess alterations in catalase and glutathione levels, nitrite concentration, and the activity of matrix metalloproteinases (MMP) 2 and 9. Besides, histopathological studies were done to evaluate the number of neurons in the spinal cord tissue. Results and discussion: Various doses of SIL, particularly the 0.2 μmol dosage, significantly influenced the alleviation of pain, enhancement of motor function, and weight gain in animals following SCI. In addition, SIL increased the levels of catalase and glutathione, while decreasing serum nitrite levels. It also increased anti-inflammatory MMP2 levels and the sensory/motor neurons' survival, while decreasing inflammatory MMP9. Conclusion: Generally, intrathecal injection of SIL after SCI provides neuroprotective, anti-inflammatory, and antioxidant effects leading to pain reduction and improved motor function in rats.
Indexed as
Identifiers
What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.